– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechn ...

证 券 研 究 报 告 赛道百花齐放，潜力靶点或迎新突破 ——癫痫药物行业深度报告 证券分析师： 张静含 A0230522080004 凌静怡 A0230522060001 2025.6.17 投资案件 www.swsresearch.com 证券研究报告 2 ◼ 癫痫是神经系统常见疾病，患者人数众多。根据《柳叶刀-公共卫生》数据统计：2021年，全球有 5170万人患有癫痫，年龄标准化患病率为658/10万人。据中国抗癫痫协会数据，中国约有900万左 右的癫痫患者，其中500-600万是活动性癫痫患者，同时每年新增加癫痫患者约40万，在中国癫痫 已经成为神经科仅次于头痛的第二大常见病。 ◼ 癫痫的发病机制复杂多样，存在较大治疗缺口。癫痫发病机制复杂多样，包括离子通道异常、中枢 神经系统兴奋性/抑制性神经递质分泌不平衡、神经环路异常，以及神经炎症和神经胶质细胞异常等， 抗癫痫发作药物（ASMs）是目前最重要和最基本的治疗手段，但疗效有限、副作用明显等问题依然 影响着癫痫患者的治疗效果。我国癫痫病人经单药序贯或多药联合治疗后，仍有30%的癫痫患者发 作无法得到有效控制，治疗存在着较大缺口。 ◼ 抗癫痫药物在研管 ...

Biogen (BIIB) reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate of $3.32.Earnings declined 18% year over year on a reported basis, owing to costs related to an upfront payment of $165 million made to Stoke Therapeutics (STOK) . BIIB entered into a collaboration agreement with STOK for the development and commercialization of the latter’s pipeline candidate, zorevunersen for treating Dravet syndrome in February. (Find the latest EPS estimates an ...

Biogen (BIIB) will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's earnings beat expectations by 0.58%. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $2.24 billion and $3.34 per share, respectively. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Factors to Consider for BiogenIn the first quarter, lower sales of multiple sclerosis (“MS”) drugs are likely to have been offset by revenues ...